Treatment of local recurrenct nasopharyngeal carcinoma after radiotherapy

doi:10.3760/cma.j.cn371439-20190926-00007

Abstract

Abstract:

The local control rate of nasopharyngeal carcinoma in the period of accurate intensity modulated radiotherapy is very high. Only 10% to 20% of the patients will have local or lymph node recurrence after the first radiotherapy. Locally recurrent nasopharyngeal carcinoma is still potentially curable. However, the retreatment of locally recurrent nasopharyngeal carcinoma needs to be optimized. According to the latest clinical research evidence, we explore the recurrence pattern of nasopharyngeal carcinoma and the choice of treatment of locally recurrent nasopharyngeal carcinoma.

Key words: Nasopharyngeal neoplasms, Radiotherapy, Neoplasm recurrence,local

Shen Jianjun. Treatment of local recurrenct nasopharyngeal carcinoma after radiotherapy[J]. Journal of International Oncology, 2020, 47(4): 227-230.

References 25

[1]	Sun XS, Liu SL, Luo MJ , et al. The association between the development of radiation therapy, image technology, and chemotherapy, and the survival of patients with nasopharyngeal carcinoma: a cohort study from 1990 to 2012[J]. Int J Radiat Oncol Biol Phys, 2019,105(3):581-590. DOI: 10.1016/j.ijrobp.2019.06.2549.
[2]	Sun XS, Liu DH, Liu SL , et al. Patterns of failure and survival trends in 3,808 patients with stage Ⅱ nasopharyngeal carcinoma diagnosed from 1990 to 2012: a large-scale retrospective cohort study[J]. Cancer Res Treat, 2019,51(4):1449-1463. DOI: 10.4143/crt.2018.688. doi: 10.4143/crt.2018.688
[3]	Yao JJ, Qi ZY, Liu ZG , et al. Clinical features and survival outcomes between ascending and descending types of nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: a big-data intelligence platform-based analysis[J]. Radiother Oncol, 2019,137:137-144. DOI: 10.1016/j.radonc.2019.04.025.
[4]	Miszczyk L, Namysł-Kaletka A, Napieralska A , et al. Stereotactic ablative radiotherapy for prostate cancer-the treatment results of 500 patients and analysis of failures[J]. Technol Cancer Res Treat, 2019,18: 1533033819870815. DOI: 10.1177/1533033819870815.
[5]	Au KH, Ngan RKC, Ng AWY , et al. Treatment outcomes of nasopharyngeal carcinoma in modern era after intensity modulated radiotherapy (IMRT) in Hong Kong: a report of 3328 patients (HKNPCSG 1301 study)[J]. Oral Oncol, 2018,77:16-21. DOI: 10.1016/j.oraloncology.2017.12.004.
[6]	Agas RAF, Yu KKL, Sogono PG , et al. Reirradiation for recurrent nasopharyngeal carcinomas: experience from an academic tertiary center in a low- to middle-income country[J]. J Glob Oncol, 2019,5:1-14. DOI: 10.1200/JGO.18.00191.
[7]	Dionisi F, Croci S, Giacomelli I , et al. Clinical results of proton therapy reirradiation for recurrent nasopharyngeal carcinoma[J]. Acta Oncol, 2019,58(9):1238-1245. DOI: 10.1080/0284186X.2019.1622772.
[8]	Kong L, Hu J, Guan X , et al. Phase Ⅰ/Ⅱ trial evaluating carbon ion radiotherapy for salvaging treatment of locally recurrent nasopharyngeal carcinoma[J]. J Cancer, 2016,7(7):774-783. DOI: 10.7150/jca.14399.
[9]	Tian YM, Huang WZ, Yuan X , et al. The challenge in treating locally recurrent T3-4 nasopharyngeal carcinoma: the survival benefit and severe late toxicities of re-irradiation with intensity-modulated radiotherapy[J]. Oncotarget, 2017,8(26):43450-43457. DOI: 10.18632/oncotarget.15896.
[10]	Gebhardt BJ, Vargo JA, Ling D , et al. Carotid dosimetry and the risk of carotid blowout syndrome after reirradiation with head and neck stereotactic body radiation therapy[J]. Int J Radiat Oncol Biol Phys, 2018,101(1):195-200. DOI: 10.1016/j.ijrobp.2017.11.045. doi: 10.1016/j.ijrobp.2017.11.045
[11]	Li YQ, Tian YM, Tan SH , et al. Prognostic model for stratification of radioresistant nasopharynx carcinoma to curative salvage radiotherapy[J]. J Clin Oncol, 2018,36(9):891-899. DOI: 10.1200/JCO.2017.75.5165. doi: 10.1200/JCO.2017.75.5165
[12]	Pratx G, Kapp DS . Ultra-high-dose-rate FLASH irradiation may spare hypoxic stem cell niches in normal tissues[J]. Int J Radiat Oncol Biol Phys, 2019,105(1):190-192. DOI: 10.1016/j.ijrobp.2019.05.030. doi: 10.1016/j.ijrobp.2019.05.030
[13]	Ng WT, Wong ECY, Cheung AKW , et al. Patterns of care and treatment outcomes for local recurrence of NPC after definite IMRT-a study by the HKNPCSG[J]. Head Neck, 2019,41(10):3661-3669. DOI: 10.1002/hed.25892. doi: 10.1002/hed.v41.10
[14]	Chan JYW, Wong STS, Wei WI . Surgical salvage of recurrent T3 nasopharyngeal carcinoma: prognostic significance of clivus, maxillary, temporal and sphenoid bone invasion[J]. Oral Oncol, 2019,91:85-91. DOI: 10.1016/j.oraloncology.2019.02.023. doi: 10.1016/j.oraloncology.2019.02.023
[15]	Ganpule A, Patil A, Singh A , et al. Robotic-assisted kidney transplant: a single center experience with median follow-up of 2.8 years[J]. World J Urol, 2019, In press. DOI: 10.1007/s00345-019-02934-0.
[16]	Bickerton R, Ahmed S, Kholief A , et al. Breadth and depth: three-dimensional endoscopic field of view: two-dimensional versus three-dimensional endoscopic field of view[J]. World Neurosurg, 2019,127:e717-e721. DOI: 10.1016/j.wneu.2019.03.247. doi: 10.1016/j.wneu.2019.03.247
[17]	Salom MC, López F, Pacheco E , et al. Salvage surgery in the treatment of local recurrences of nasopharyngeal carcinomas[J]. Acta Otorrinolaringol Esp, 2018,69(6):339-344. DOI: 10.1016/j.otorri.2017.11.006. doi: 10.1016/j.otorri.2017.11.006
[18]	Kang MK, Ahn YC, Park W , et al. High dose radiation therapy concurrent with chemotherapy in locally advanced nasopharynx cancer[J]. Cancer Res Treat, 2003,35(5):391-399. DOI: 10.4143/crt.2003.35.5.391. doi: 10.4143/crt.2003.35.5.391
[19]	Peng H, Tang LL, Liu X , et al. Anti-EGFR targeted therapy delivered before versus during radiotherapy in locoregionally advanced nasopharyngeal carcinoma: a big-data, intelligence platform-based analysis[J]. BMC Cancer, 2018,18(1):323. DOI: 10.1186/s12885-018-4268-y. doi: 10.1186/s12885-018-4268-y
[20]	Hui EP, Ma BBY, Loong HHF , et al. Efficacy, safety, and pharmacokinetics of axitinib in nasopharyngeal carcinoma: a preclinical and phase Ⅱ correlative study[J]. Clin Cancer Res, 2018,24(5):1030-1037. DOI: 10.1158/1078-0432.CCR-17-1667. doi: 10.1158/1078-0432.CCR-17-1667
[21]	Ng WT, Ngan RKC, Kwong DLW , et al. Prospective, multicenter, phase 2 trial of induction chemotherapy followed by bio-chemoradiotherapy for locally advanced recurrent nasopharyngeal carcinoma[J]. Int J Radiat Oncol Biol Phys, 2018,100(3):630-638. DOI: 10.1016/j.ijrobp.2017.11.038. doi: 10.1016/j.ijrobp.2017.11.038
[22]	Hsu C, Lee SH, Ejadi S , et al. Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1-positive nasopharyngeal carcinoma: results of the KEYNOTE-028 study[J]. J Clin Oncol, 2017,35(36):4050-4056. DOI: 10.1200/JCO.2017.73.3675. doi: 10.1200/JCO.2017.73.3675
[23]	Ma BBY, Lim WT, Goh BC , et al. Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma: an international, multicenter study of the mayo clinic phase 2 consortium (NCI-9742)[J]. J Clin Oncol, 2018,36(14):1412-1418. DOI: 10.1200/JCO.2017.77.0388. doi: 10.1200/JCO.2017.77.0388
[24]	Fang W, Yang Y, Ma Y , et al. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials[J]. Lancet Oncol, 2018,19(10):1338-1350. DOI: 10.1016/S1470-2045(18)30495-9.
[25]	Finazzi T, Rordorf T, Ikenberg K , et al. Radiotherapy-induced anti-tumor immune response and immune-related adverse events in a case of recurrent nasopharyngeal carcinoma undergoing anti-PD-1 immunotherapy[J]. 2018,18(1):395. DOI: 10.1186/s12885-018-4295-8.